Effect of Endogenous GLP-1 on Insulin Secretion in Type 2 Diabetes by Salehi, Marzieh et al.
Effect of Endogenous GLP-1 on Insulin Secretion in
Type 2 Diabetes
Marzieh Salehi,
1 Benedict Aulinger,
1 Ronald L. Prigeon,
2 and David A. D’Alessio
1
OBJECTIVE—The incretins glucagon-like peptide-1 (GLP-1)
and glucose-dependent insulinotropic polypeptide (GIP) account
for up to 60% of postprandial insulin release in healthy people.
Previous studies showed a reduced incretin effect in patients
with type 2 diabetes but a robust response to exogenous GLP-1.
The primary goal of this study was to determine whether
endogenous GLP-1 regulates insulin secretion in type 2 diabetes.
METHODS—Twelve patients with well-controlled type 2 diabe-
tes and eight matched nondiabetic subjects consumed a break-
fast meal containing D-xylose during ﬁxed hyperglycemia at 5
mmol/l above fasting levels. Studies were repeated, once with
infusion of the GLP-1 receptor antagonist, exendin-(9–39) (Ex-9),
and once with saline.
RESULTS—The relative increase in insulin secretion after meal
ingestion was comparable in diabetic and nondiabetic groups
(44  4% vs. 47  7%). Blocking the action of GLP-1 suppressed
postprandial insulin secretion similarly in the diabetic and non-
diabetic subjects (25  4% vs. 27  8%). However, Ex-9 also
reduced the insulin response to intravenous glucose (25  5% vs.
26  7%; diabetic vs. nondiabetic subjects), when plasma GLP-1
levels were undetectable. The appearance of postprandial in-
gested D-xylose in the blood was not affected by Ex-9.
CONCLUSIONS—These ﬁndings indicate that in patients with
well-controlled diabetes, the relative effects of enteral stimuli
and endogenous GLP-1 to enhance insulin release are retained
and comparable with those in nondiabetic subjects. Surprisingly,
GLP-1 receptor signaling promotes glucose-stimulated insulin
secretion independent of the mode of glucose entry. Based on
rates of D-xylose absorption, GLP-1 receptor blockade did not
affect gastric emptying of a solid meal. Diabetes 59:1330–1337,
2010
G
lucagon-like peptide 1 (GLP-1) is a gut-brain
peptide that is a major component of the incre-
tin effect and is essential for normal glucose
tolerance (1). Based on studies in which syn-
thetic GLP-1, or GLP-1 receptor (GLP-1r) agonists, is
administered to humans, GLP-1 has a broad range of
actions that promote glucose homeostasis, including stim-
ulating insulin secretion (2), suppressing glucagon release
(3–4), delaying gastric emptying (5), and increasing he-
patic glucose balance (6–7). Importantly, and unlike other
insulinotropic gut peptides, the effects of GLP-1 on glucose
metabolism are retained in people with diabetes (8–10).
This has led to the development of novel therapeutic
compounds for use in diabetic patients that are based on
GLP-1r signaling (11).
The physiologic role of GLP-1 in individuals with diabe-
tes has not been determined. However, there are several
reasons to question whether the GLP-1 system is fully
functional in this patient group. First, there is some
evidence that GLP-1 secretion in response to meal inges-
tion in type 2 diabetes is impaired (12–15), although this
ﬁnding has not been uniform (16–17). Second, the sensi-
tivity of insulin secretion to exogenous GLP-1 is reduced in
diabetic individuals (18). Finally, it has long been believed
that the augmentation of glucose-stimulated insulin secre-
tion during enteral glucose absorption, the incretin effect,
is severely attenuated in type 2 diabetes, implying that
incretins such as GLP-1 are not normally active in this
group of subjects.
In this study, we tested the hypothesis that the effect of
endogenous GLP-1 to promote insulin secretion after meal
ingestion is reduced in people with diabetes. Diabetic
subjects and age- and weight-matched nondiabetic sub-
jects were studied with and without infusion of the spe-
ciﬁc GLP-1r antagonist, exendin-(9–39) (Ex-9), during
ﬁxed hyperglycemia before and after a breakfast meal.
RESEARCH DESIGN AND METHODS
Subjects. Twelve subjects with established type 2 diabetes (ﬁve females and
seven males) and eight age- and BMI-matched nondiabetic subjects (six
females and two males) were studied on two separate days (Table 1). All
subjects were weight stable for 3 months prior to the experiments. Diabetic
patients had good glycemic control with a mean A1C level of 6.3  0.1% (range
5.9–7.6%). Normal glucose tolerance was conﬁrmed in the nondiabetic sub-
jects by a 2-h venous plasma glucose level of 7.8 mmol/l after a 75-g oral
glucose tolerance test. The control subjects had no family history of type 2
diabetes, were free of any chronic medical conditions such as coronary artery
disease, uncontrolled dyslipidemia, or hypertension, and received no medica-
tions for any of these conditions. The studies were approved by the institu-
tional review board of the University of Cincinnati, and all participants
provided written informed consent prior to the studies.
Peptides. Synthetic exendin-(9–39) (Clinalfa; Merck Biosciences AG,
La ¨ufelﬁngen, Switzerland) was greater than 95% pure, sterile, and free of
pyrogens. Lyophilized peptide was prepared in 0.25% human serum albumin
on the day of study. The use of synthetic Ex-9 is approved under the U.S. Food
and Drug Administration Investigational New Drug 65,837.
Experimental procedures. Subjects were instructed to consume greater
than 200 g of carbohydrate for 3 days before each visit and not to engage in
vigorous physical activity. Subjects with diabetes withheld their oral antidia-
betic medication for 3 days before each study. They were admitted to the
General Clinical Research Center at Cincinnati Children’s Hospital on sepa-
rate occasions after an overnight fast. Intravenous catheters were placed in
each forearm for the withdrawal of blood and the infusion of glucose and
Ex-9; the arm used for blood sampling was continuously warmed using a
heating pad to arterialize the venous blood. After removal of fasting blood
samples, a primed continuous infusion of 20% glucose was started to achieve
and maintain a target blood glucose concentration of 5 mmol/l greater than
fasting levels (19). At 30 min, subjects received either 1) an intravenous bolus
of synthetic Ex-9 (7,500 pmol/kg) for 1 min followed by a continuous infusion
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(19). The order of the infusions was balanced so that half the subjects received
saline or Ex-9 as their ﬁrst infusion, and the two experiments were separated
by an interval of at least 1 week. At 90 min, subjects consumed a mixed
nutrient breakfast (300 kcal with a calorie distribution of 40% carbohydrate,
20% protein, and 40% fat) consisting of scrambled eggs, English mufﬁn,
margarine, chocolate pudding mixed with 10 g D-xylose, and milk that was
eaten within 10 min. Subjects were instructed to consume the pudding in the
middle of the meal. The rate of intravenous glucose infusion was adjusted to
maintain the blood glucose at the target rate throughout the meal and for the
remainder of the study. Blood samples were drawn at 10, 5, 0, 15, 30, 45,
60, 70, 75, 80, 85, 90, 95,100, 105, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200,
210, 220, 230, 240, 250, 255, 260, 265, and 270 min; the plasma was separated
within 60 min of blood withdrawal and stored at 80°C until assay. Blood
samples were collected in tubes containing heparin, 50 mmol/l EDTA, and 500
kallikrein inhibitory units per milliliter of aprotinin.
Assays. Blood glucose concentrations were determined by a glucose oxidase
method using a glucose analyzer (YSI 2300 STAT Plus; Yellow Springs
Instruments, Yellow Springs, OH). Insulin, glucagon, total GLP-1, and C-
peptide were measured by radioimmunoassays as described previously (19).
D-xylose was measured by colorimetric assay (20), and total glucose-depen-
dent insulinotropic polypeptide (GIP) was measured by ELISA (Linco Re-
search, St. Charles, MO).
Calculations and analysis. Insulin secretion rates (ISRs) were derived from
plasma C-peptide concentrations using deconvolution with population esti-
mates of C-peptide clearance (21–22). Fasting concentrations of blood glu-
cose, hormones, and ISR were taken as the mean of the three samples drawn
at 10, 5, and 0 min. Preprandial insulin secretory responses were com-
puted as the mean increments above fasting values of ISR from 60 to 90 min;
these were used to determine the responses to intravenous glucose–induced
hyperglycemia. Postprandial insulin secretory responses were calculated as
the mean increments above the 60–90 min values of ISR from 95 to 270 min.
This measure of postprandial insulin secretion reﬂects the augmentation of
ISR, beyond 5 mmol/l hyperglycemia, by meal-induced stimuli, and has been
used previously as a surrogate for the incretin effect (23–25). The D-xylose,
GLP-1, and GIP concentrations from 80 to 90 min were taken as baseline, and
levels after meal consumption (95–270 min for D-xylose and GLP-1; 95–240 min
for GIP) were used to compute postprandial areas under the curve (AUC)
above baseline. The glucagon levels from 80 to 90 min (preprandial) were
compared with fasting as well as values of glucagon from 250 to 260 min. The
stability of the glucose clamps was computed as the mean of coefﬁcients of
variation for each study from 60 to 270 min. The reproducibility of the clamps
was computed as the difference in mean glucose from 60 to 270 for each
subject.
The contribution of endogenous GLP-1 to insulin secretion was determined
by comparing the mean values of ISR for each subject during infusion of saline
or Ex-9. Separate comparisons were made for the preprandial and postpran-
dial periods.
The parameters obtained from each subject in the two studies and from the
diabetic and nondiabetic groups were compared using one- and two-way
ANOVA with repeated measures. Spearman correlation was used to seek
relationships between measured outcomes and subject characteristics such as
A1C, and paired t test was used to compare measured variables within each
study. Data are presented as the mean  SEM.
RESULTS
Fasting glucose was signiﬁcantly higher in the diabetic
than in the nondiabetic subjects (P  0.001), but fasting
insulin and C-peptide concentrations were comparable,
and the values for each subject were similar on the days of
the saline and Ex-9 studies (Table 2). Blood glucose
concentrations were raised by 5 mmol/l from fasting
values to hyperglycemic levels from 60 to 270 min that
were comparable during the Ex-9 and saline studies (Fig.
1, Table 2). The average clamped glucose levels (60–270
min) for nondiabetic subjects during the saline and Ex-9
studies were 9.3  0.2 and 9.3  0.2 mmol/l, respectively,
with a mean difference of 0.02  0.03 mmol/l. For the
diabetic subjects, the mean glucose concentrations (60–
270 min) were 12.0  0.4 and 12.1  0.4 mmol/l for the
control and Ex-9 clamps, respectively, and the mean
difference was 0.09  0.07 mmol/l. The average coefﬁcient
of variation of the glucose concentrations during the
hyperglycemic clamp control studies was 4.4  0.4% for
the nondiabetic and 4.9  0.5% for the diabetic subjects.
The glucose infusion rates needed to reach target gly-
cemia were higher in the nondiabetic compared with
diabetic subjects during the preprandial (60–90 min; P 
0.01) and postprandial (95–270 min; P  0.05) periods.
Infusion of Ex-9 was associated with a signiﬁcant reduc-
tion of the glucose infusion rates necessary to maintain
target glycemia from 60 to 90 min in both groups (P  0.05
for both comparisons). After ingestion of the breakfast
meal, the glucose infusion rate was initially reduced in
some subjects to compensate for glucose inﬂux from the
gut, but was signiﬁcantly higher than preprandial infusions
by the end of the study (Fig. 1, Table 2).
In both the diabetic and nondiabetic groups, -cell
secretion rose in response to intravenous glucose admin-
istration to a plateau from 60 to 90 min (Fig. 2, Table 2);
preprandial insulin, C-peptide, and ISR were greater in the
nondiabetic than the diabetic group (P  0.05). Among the
diabetic subjects, there were signiﬁcant inverse correla-
tions between the preprandial insulin secretory response
and fasting glucose (r  0.7, P  0.01) and A1C (r 
0.8, P  0.05). Compared with the study with saline
infusion, GLP-1r blockade with Ex-9 caused a signiﬁcant
reduction of insulin secretion before meal ingestion
(60–90 min), as indicated by signiﬁcantly lower mean
values of insulin, C-peptide, and ISR (Table 2). The GLP-1
effect on intravenous glucose–stimulated insulin secretion,
taken as the percentage difference in mean ISR from 60 to
90 min with and without Ex-9, was 25  5% in diabetic
subjects and 26  7% in the nondiabetic group (Fig. 3).
After meal consumption (95–270 min), -cell secretion
increased signiﬁcantly over preprandial (60–90 min) val-
ues in both the nondiabetic (P  0.01) and diabetic (P 
0.05) subjects; although the absolute responses were sig-
niﬁcantly lower in the diabetic group (P  0.05; Fig. 2,
Table 2). Among the diabetic subjects, there were signiﬁ-
cant inverse correlations between postprandial insulin
secretory responses and A1C (r  0.6, P  0.05). During
the saline infusion study, meal ingestion signiﬁcantly en-
hanced ISR, by 47  7% in the nondiabetic and 44  4% for
diabetic subjects, above preprandial ISR. During the Ex-9
infusion, postprandial ISR was 44  6% and 45  4% higher
than preprandial ISR in the nondiabetic and diabetic
groups, respectively. Blocking endogenous GLP-1 with
Ex-9 diminished postprandial ISR by 27  8% in nondia-
betic and 25  4% in diabetic subjects, compared with the
studies with saline infusion (Fig. 3).
Fasting glucagon concentrations in the diabetic subjects
were similar during the saline and Ex-9 studies (Table 2).
During both the saline and Ex-9 infusions, the hyperglyce-
mic clamp suppressed glucagon levels from 80 to 90 min
(P  0.05). Glucagon values at the conclusion of the
experiments remained suppressed during the saline infu-
TABLE 1
Characteristics of the study participants
Patients with
type 2 diabetes
Nondiabetic
subjects
Age (year) 54 (41–63) 49 (34–60)
BMI (kg/m
2) 34 (26–44) 32 (24–41)
Sex (F/M) 5/7 6/2
Duration of diabetes (month) 50 (1–200)
Sulfonylurea/metformin/diet 4/9/3
Data are presented as mean (range) unless otherwise noted.
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(P  0.05). In nondiabetic subjects, plasma glucagon
concentrations decreased slightly, but not signiﬁcantly,
between the fasting and preprandial periods, and did not
change further after the meal, with either saline or Ex-9.
Plasma concentrations of D-xylose increased steadily
after meal intake and peaked at 60 min after meal con-
sumption in both diabetic and nondiabetic subjects during
both saline and Ex-9 studies (Fig. 4). The area under
plasma D-xylose curve in the studies with saline and Ex-9
infusion, respectively, were 105  8.2 and 102  9.1
mmol/l/min in diabetic and 71  8.5 and 70  8 mmol/l/min
in nondiabetic subjects, indicating that GLP-1 receptor
blockade had minimal effects on the passage of D-xylose
from the stomach to the intestine. D-xylose AUC was
signiﬁcantly greater in the diabetic compared with the
nondiabetic group (P  0.05).
Fasting plasma GIP levels were comparable before meal
ingestion in the studies with saline and Ex-9 infusion in the
diabetic (16  1 and 16  2 pmol/l) and nondiabetic (20 
1 and 20  2 pmol/l) subjects. In both the nondiabetic and
diabetic groups, meal consumption caused a similar rise of
GIP concentrations in the saline and Ex-9 studies (Fig. 4,
Table 2), suggesting that GLP-1r blockade had no effect on
GIP secretion. The GIP response was signiﬁcantly greater
in the diabetic compared with nondiabetic group (P 
0.05). Fasting plasma GLP-1 were not different in the
diabetic (3.6  0.3 and 3.6  0.2 pmol/l) and nondiabetic
(3.1  0.1 and 3.0  0.0 pmol/l) groups, during the saline
and Ex-9 studies, but levels were undetectable in 80% of
the subjects. Plasma GLP-1 increased after meal ingestion
in both groups (Fig. 4, Table 2), and Ex-9 infusion signif-
icantly increased these responses in the nondiabetic and
diabetic subjects (P  0.05).
Subjects tolerated the experiments without notable
problems, and there were no adverse events associated
with Ex-9 infusion.
DISCUSSION
The current study investigated the role of endogenous
GLP-1 on islet hormone secretion and gastric emptying in
patients with type 2 diabetes. Although previous studies
have demonstrated that diabetic patients respond to phar-
macologic amounts of GLP-1, the effect of endogenous
GLP-1 has not been previously demonstrated. Our results
indicate that in diabetic subjects with good glycemic
control, there is an enhancement of glucose-stimulated
insulin secretion after meal ingestion that is similar on a
relative basis to nondiabetic individuals. Moreover, the
TABLE 2
Effect of meal ingestion during hyperglycemic clamp on -cell hormonal response and gastrointestinal peptides in studies with and
without intravenous Ex-9 in subjects with and without diabetes
Time interval (min)
Diabetic subjects Nondiabetic subjects Statistical effects (P values)
Saline Ex-9 Saline Ex-9
Ex-9 vs.
Saline
Diabetic vs.
nondiabetic
subjects Interaction
Glucose (mmol/l)
Fasting 6.7  0.3 6.5  0.3 4.8  0.2 4.9  0.1 NS 0.001 NS
60–90 12.3  0.3 12.2  0.3 9.3  0.2 9.5  0.2 NS 0.001 NS
95–270 12.0  0.4 12.1  0.4 9.3  0.2 9.3  0.2 NS 0.001 NS
GINF (mg/kg/min)
60–90 3.9  0.4 3.5  0.4 6.0  0.5 5  0.5 0.05 0.01 NS
95–270 6.1  1.6 4.6  1.4 11.5  0.7 9.6  0.9 0.01 0.05 NS
Insulin (pmol/l)
Fasting 128  22 142  28 111  20 116  21 NS NS NS
60–90 363  69 207  32 719  134 490  107 0.001 0.01 NS
95–270 894  220 577  94 2,243  365 1,531  287 0.001 0.01 0.05
C-peptide (nmol/l)
Fasting 1.2  0.1 1.0  0.1 0.9  0.1 0.9  0.2 0.09 NS NS
60–90 2.1  0.3 1.8  0.2 3.2  0.4 2.6  0.4 0.001 0.05 NS
95–270 4.6  1.1 3.4  0.6 7.6  0.9 5.9  1.1 0.01 0.05 NS
ISR (nmol/min)
Fasting 0.34  0.03 0.35  0.04 0.47  0.11 0.49  0.13 NS NS NS
60–90 0.71  0.1 0.53  0.08 1.20  0.17 0.95  0.2 0.001 0.05 NS
95–270 1.43  0.32 1.03  0.18 2.42  0.32 1.83  0.36 0.01 0.05 NS
Glucagon (pg/ml)
Fasting 48  44 9  44 6  45 1  5N SN S N S
80–90 41  34 1  44 3  24 2  3N SN S N S
250–260 43  45 8  84 0  44 1  5 0.05 NS 0.06
GLP-1 (pmol/l)
80–90 3.6  0.3 3.6  0.2 3.1  0.1 3.0  0.0 NS NS NS
AUCGLP-1 (pmol/l/min)
95–270 438  92 1,423  340 154  73 560  230 0.05 0.08 NS
GIP (mol/l)
80–90 0.07  0.0 0.06  0.0 0.05  0.0 0.04  0.0 NS NS NS
AUCGIP (mol/l/min)
95–240 12.7  1.4 17.1  1.4 7.9  1.9 7.7  2.3 NS 0.05 NS
GINF, glucose infusion rate; NS, not signiﬁcant.
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groups, indicating that endogenous GLP-1 contributes
signiﬁcantly to postprandial insulin secretion in diabetic
subjects. Surprisingly, GLP-1r blockade reduced insulin
secretion in response to intravenous glucose alone, and
the magnitude of this effect was as great as that on
postprandial -cell responses. Gastric emptying, as re-
ﬂected by D-xylose uptake, was not affected by blocking
GLP-1r. These ﬁndings support an important physiologic
role for GLP-1 to amplify glucose-stimulated insulin secre-
tion, and demonstrate that this effect is retained in at least
a subset of type 2 diabetic patients.
Our group and others (4,19,26–27) have previously used
Ex-9 to demonstrate the effects of GLP-1r signaling in
human subjects. In our previous report, we demonstrated
that doses of Ex-9 identical to those used in the present
study were effective for blocking supraphysiologic infu-
sions of GLP-1 nearly completely, and for reducing post-
prandial insulin secretion by 30%. Although no one has
established deﬁnitively a dose of Ex-9 beyond which no
further inhibition of GLP-1 action can be detected, based
on previously published results (4,19,26) we believe that
the dose used in this study was near maximal for what can
be achieved in an acute infusion.
The classic method for determining the incretin effect is
a 2-day method with an oral glucose tolerance test on day
1 followed on day 2 by an intravenous glucose infusion
isoglycemic to arterialized venous glucose levels after
glucose ingestion (28). Using this method, Nauck et al.
demonstrated a severe impairment of the incretin effect in
subjects with type 2 diabetes (29), a much cited ﬁnding
that has been very inﬂuential in shaping the understanding
of enteroinsular physiology. We elected to use an alterna-
tive method, the hyperglycemic clamp-meal test, as a
means of comparing the relative increase in insulin secre-
tion when carbohydrate is absorbed enterally, because the
test can be performed in a single morning, reducing
day-to-day variability and the time commitment of re-
search subjects. Variations of this method have been used
previously by a number of investigators (23–25). Our
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FIG. 1. Blood glucose concentrations and glucose infusion rates during intravenous-meal clamps with Ex-9 or saline infusions in nondiabetic (left)
and diabetic (right) subjects. Data are presented as mean  SEM.
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onstrate that the estimation of the incretin effect using the
1-day and 2-day methods is comparable with a strong and
signiﬁcant within-subject correlation (30). In the present
study, we used a mixed nutrient meal as the enteral
stimulus during the hyperglycemic clamp to assess the
nutrient, incretin, and neural responses activated by typi-
cal food consumption. We targeted the clamp as 5 mmol/l
above fasting glucose to achieve levels that were slightly
greater than what we expected as a result of meal inges-
tion alone. Overall, this design permitted a measure of the
enhancement of insulin secretion by meal ingestion, and
the GLP-1 component of it. Without further validation, this
measure cannot be equated to the classically derived
incretin effect, although we believe that the two methods
assess similar physiologic processes.
In contrast to what was described originally by Nauck et
al. (29), and conﬁrmed in more recent studies (13), the
cohort of diabetic subjects described here had a compa-
rable degree of meal enhancement of insulin secretion to
the nondiabetic group. Although -cell secretion was
clearly abnormal in diabetic compared with the nondia-
betic subjects, relative to the ISR or plasma insulin levels
achieved during stimulation with intravenous glucose
alone, meal ingestion caused equivalent augmentation in
the diabetic and nondiabetic groups (Table 2). This ﬁnding
is consistent with the results reported by Perley and Kipnis
more than three decades ago (31), showing that obese
subjects with mild type 2 diabetes had preserved stimula-
tion of insulin secretion by alimentary factors relative to
nondiabetic control subjects. In contrast to the ﬁndings of
Nauck et al. (29), the plasma GIP responses were in-
creased in our diabetic compared with nondiabetic sub-
jects. Increased GIP secretion has been reported
previously in some studies of diabetic subjects (reviewed
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FIG. 2. -cell secretion in response to hyperglycemia and meal ingestion with and without Ex-9 infusion. Plasma insulin concentrations (A) and
insulin secretion rates (B) for nondiabetic (left) and diabetic (right) subjects. Data are presented as mean  SEM.
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FIG. 3. The contribution of GLP-1 to preprandial and postprandial
insulin secretion. The percentage reduction of insulin secretion rates
by Ex-9 is shown for the preprandial (60–90 min) and postprandial
(95–270 min) periods in the nondiabetic (black bars) and diabetic
(gray bars) groups. Data are presented as mean  SEM.
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for a bigger augmentation of insulin secretion by meal
ingestion in our diabetic subjects, most previous studies
indicate that GIP has very modest effects on insulin
secretion in type 2 diabetes (8).
Just as the relative increase of ISR with meal ingestion
was similar in the diabetic and nondiabetic subjects, so
too was the contribution of GLP-1 action to postprandial
-cell responses. Based on the effects of Ex-9, GLP-1
accounted for 25% of the insulin response to the mixed
meal at a ﬁxed level of hyperglycemia. This is consistent
with what we reported recently as the GLP-1 effect in
healthy lean subjects during an oral glucose tolerance test
(19). The ﬁnding of intact effects of GLP-1 in the diabetic
group was unexpected, in that previous work had indi-
cated that type 2 diabetic subjects have a blunted response
to exogenous GLP-1 infused to supraphysiologic levels
(18). Although there was a weak trend toward the diabetic
group having a greater postprandial GLP-1 response, there
was considerable heterogeneity in the AUC among the
subjects and no correlation between this measure and
insulin secretion or the magnitude of insulin suppression
by GLP-1 receptor blockade. These results suggest that
circulating GLP-1 may not be a good predictor of the
physiologic response to endogenous peptide.
The most surprising ﬁnding in this study was that Ex-9
diminished insulin secretion in response to intravenous
glucose–induced hyperglycemia before meal consump-
tion, at a time when circulatory levels of GLP-1 were often
undetectable. In fact, the relative effect of GLP-1r blockade
on preprandial and postprandial ISR was nearly identical.
These ﬁndings indicate that GLP-1r effects on the -cell are
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FIG. 4. Postprandial concentrations of D-xylose (A), GIP (B), and GLP-1 (C) in nondiabetic (left) and diabetic (right) subjects. Data are
presented as mean  SEM.
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enteral nutrient absorption when circulating levels of
GLP-1 increase. It is important to note that in previous
studies blockade of the GLP-1 receptor did not affect
fasting plasma insulin levels (4,27,33), but that Schirra et
al. noted a reduction in plasma insulin, similar to what we
describe here, during a hyperglycemic clamp when Ex-9
was infused (27). Thus, when considered together, the
current evidence supports a role for GLP-1r signaling to
potentiate glucose-stimulated but not basal insulin secre-
tion in humans. This is consistent with studies in mice with
engineered deletion of the GLP-1r gene in which similar
degrees of glucose intolerance have been described to
both oral and intraperitoneal glucose challenges (34),
conditions with elevated and basal plasma GLP-1 levels,
respectively. The mechanism whereby Ex-9 affects insulin
secretion in the absence of elevated circulating levels of
GLP-1 is unclear. However, recent studies raise the possi-
bility of neural (35–36) and paracrine (37) modes of GLP-1
signaling, either of which could be affected by GLP-1r
blockade. In addition, in vitro work suggests that Ex-9 can
act as an inverse agonist in isolated mouse islets (38).
Overall, our ﬁndings ﬁt with an expanded model of -cell
regulation by GLP-1 that stretches beyond endocrine ef-
fects after eating.
Although several investigators have suggested that the
predominant effect of GLP-1 on glucose control is based
on its effect on gastric emptying (39–40), this conjecture is
based on the results of studies using exogenous adminis-
tration of GLP-1. Given the identical pattern of postpran-
dial plasma D-xylose in our subjects with and without Ex-9,
endogenous GLP-1 has no detectable effect on the rate of
passage of nutrients from the stomach to the intestine.
Appearance of ingested D-xylose followed a similar time
course in diabetic and nondiabetic subjects, but D-xylose
reached higher concentrations in the diabetic group, sug-
gesting more rapid gastric emptying in patients with early
or mild diabetes, compatible with previous reports (41–
42). The lack of effect of Ex-9 to alter D-xylose appearance
is similar to what we have reported previously in studies
with GLP-1 blockade in healthy humans and nonhuman
primates given liquid glucose solution (19,33). We have
extended these ﬁndings in this study by using a solid meal,
and our data stand against an important physiologic role
for GLP-1 in the regulation of prandial gastric motility in
humans. However, Deane et al. have recently published
evidence that endogenous GLP-1 delays gastric emptying
in healthy subjects after a solid carbohydrate meal (43).
Because these investigators used scintigraphy, the gold
standard for measuring gastric emptying, our ﬁndings
must be interpreted cautiously. Nonetheless, our results
are consistent with a recent report that gastric emptying in
diabetic patients was not affected by administration of a
dipeptidyl peptidase-4 inhibitor that enhanced endogenous
GLP-1 by threefold (44).
In previous studies, we and others (4,19) have found
that infusion of Ex-9 during oral or intestinal glucose
administration increases postprandial plasma glucagon,
supporting an important role for GLP-1 to regulate the
-cell. This effect was seen here, but only in the diabetic
group. The diabetic subjects had equivalent suppression of
glucagon in response to intravenous glucose during the
Ex-9 and control experiments, but after the meal there was
a signiﬁcant rise in plasma levels when the GLP-1r was
blocked. Interestingly, we did not see this latter effect in
the nondiabetic subjects. Although this outcome could
indicate differential regulation of prandial -cell secretion
in diabetes, this conclusion needs more rigorous
conﬁrmation.
In summary, we report here that administration of Ex-9
reduces insulin secretion proportionately in response to
intravenous glucose and enteral stimuli, and that this
effect is similar in diabetic and nondiabetic subjects. These
ﬁndings indicate that the effect of endogenous GLP-1 on
postprandial insulin release is preserved in patients with
well-controlled type 2 diabetes. Moreover, GLP-1r signal-
ing is important for stimulated insulin secretion indepen-
dent of the mode of glucose entry. Based on these results,
it appears that the function of the enteroinsular axis is
intact, at least in some people with type 2 diabetes, and
that the role of endogenous GLP-1 to regulate islet func-
tion is not mediated entirely by an endocrine mechanism.
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